serine palmitoyltransferase long chain base subunit 3Genealiases: C20orf38 · LCB 3 · LCB2B · LCB3 · SPT 3 · SPT3
Q-omics provides the consensus-scored SPTLC3 profile across patient tissues and cancer cell-line models. SPTLC3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPTLC3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SPTLC3 RNA expression shows 18,185 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, COAD, and KIRP as cancer lineages where SPTLC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPTLC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPTLC3 survival associations across molecular data types. SPTLC3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPTLC3 RNA expression–survival associations across cancer types. High SPTLC3 expression shows unfavorable associations in PAAD, UCEC and LIHC, but favorable associations in KIRC, ESCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPTLC3 RNA expression.
This table summarizes SPTLC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in LUAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SPTLC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPTLC3 shows lower tumor expression in COAD, LUAD, THCA, LUSC and KICH and higher tumor expression in KIRP. The COAD box plot shows higher SPTLC3 RNA expression in normal versus tumor tissue (log2 FC = −1.412, t-test p < 0.001).
This table shows molecular features associated with SPTLC3 in patient tissues and cancer cell lines. In patient samples, SPTLC3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SPTLC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and STOMACH.
